Rhumbline Advisers Xencor Inc Transaction History

Rhumbline Advisers

  • $109 Billion
  • Q3 2024

A detailed history of Rhumbline Advisers transactions in Xencor Inc stock. As of the latest transaction made, Rhumbline Advisers holds 152,257 shares of XNCR stock, worth $2.99 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
152,257
Previous 154,573 1.5%
Holding current value
$2.99 Million
Previous $2.93 Million 4.61%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024
SELL
$15.7 - $21.65 $36,361 - $50,141
-2,316 Reduced 1.5%
152,257 $3.06 Million
Q2 2024

Aug 01, 2024
BUY
$18.21 - $24.5 $77,665 - $104,492
4,265 Added 2.84%
154,573 $2.93 Million
Q1 2024

May 09, 2024
SELL
$18.65 - $26.52 $643,853 - $915,549
-34,523 Reduced 18.68%
150,308 $3.33 Million
Q4 2023

Feb 08, 2024
BUY
$16.53 - $21.42 $80,368 - $104,144
4,862 Added 2.7%
184,831 $3.92 Million
Q3 2023

Nov 09, 2023
BUY
$20.08 - $25.39 $30,883 - $39,049
1,538 Added 0.86%
179,969 $3.63 Million
Q2 2023

Aug 08, 2023
SELL
$24.77 - $29.9 $185,824 - $224,309
-7,502 Reduced 4.03%
178,431 $4.46 Million
Q1 2023

May 11, 2023
BUY
$25.95 - $36.95 $278,002 - $395,845
10,713 Added 6.11%
185,933 $5.19 Million
Q4 2022

Feb 14, 2023
SELL
$24.79 - $30.86 $18,716 - $23,299
-755 Reduced 0.43%
175,220 $4.56 Million
Q3 2022

Nov 10, 2022
BUY
$24.62 - $32.44 $124,749 - $164,373
5,067 Added 2.96%
175,975 $4.57 Million
Q2 2022

Aug 11, 2022
BUY
$19.74 - $29.01 $468,726 - $688,842
23,745 Added 16.14%
170,908 $4.68 Million
Q1 2022

May 12, 2022
BUY
$26.68 - $41.63 $284,115 - $443,317
10,649 Added 7.8%
147,163 $3.93 Million
Q4 2021

Feb 10, 2022
SELL
$33.67 - $43.44 $59,090 - $76,237
-1,755 Reduced 1.27%
136,514 $5.48 Million
Q3 2021

Nov 12, 2021
SELL
$30.65 - $35.68 $641,044 - $746,247
-20,915 Reduced 13.14%
138,269 $4.52 Million
Q2 2021

Aug 05, 2021
SELL
$34.33 - $44.68 $227,710 - $296,362
-6,633 Reduced 4.0%
159,184 $5.49 Million
Q1 2021

May 06, 2021
BUY
$40.81 - $53.88 $67,295 - $88,848
1,649 Added 1.0%
165,817 $7.14 Million
Q4 2020

Feb 10, 2021
SELL
$36.63 - $47.63 $63,369 - $82,399
-1,730 Reduced 1.04%
164,168 $7.16 Million
Q3 2020

Nov 12, 2020
SELL
$30.09 - $43.02 $104,322 - $149,150
-3,467 Reduced 2.05%
165,898 $6.44 Million
Q2 2020

Aug 13, 2020
SELL
$27.76 - $33.42 $110,901 - $133,512
-3,995 Reduced 2.3%
169,365 $5.49 Million
Q1 2020

May 06, 2020
SELL
$20.69 - $37.79 $3,972 - $7,255
-192 Reduced 0.11%
173,360 $5.18 Million
Q4 2019

Feb 05, 2020
BUY
$32.75 - $41.43 $310,732 - $393,087
9,488 Added 5.78%
173,552 $5.97 Million
Q3 2019

Oct 23, 2019
BUY
$33.73 - $46.27 $2.76 Million - $3.78 Million
81,750 Added 99.31%
164,064 $5.53 Million
Q2 2019

Aug 14, 2019
BUY
$29.6 - $40.93 $6,393 - $8,840
216 Added 0.26%
82,314 $3.37 Million
Q1 2019

May 01, 2019
BUY
$27.85 - $38.09 $275,631 - $376,976
9,897 Added 13.71%
82,098 $2.55 Million
Q4 2018

Jan 31, 2019
BUY
$32.39 - $42.05 $975,360 - $1.27 Million
30,113 Added 71.55%
72,201 $2.61 Million
Q3 2018

Nov 07, 2018
SELL
$35.69 - $47.65 $467,538 - $624,215
-13,100 Reduced 23.74%
42,088 $1.64 Million
Q2 2018

Aug 06, 2018
BUY
$28.41 - $42.41 $561,324 - $837,936
19,758 Added 55.77%
55,188 $2.04 Million
Q1 2018

May 02, 2018
SELL
$21.18 - $33.78 $16,414 - $26,179
-775 Reduced 2.14%
35,430 $1.06 Million
Q4 2017

Feb 09, 2018
SELL
$19.29 - $24.83 $136,148 - $175,250
-7,058 Reduced 16.31%
36,205 $794,000
Q3 2017

Nov 06, 2017
BUY
$19.61 - $23.35 $848,387 - $1.01 Million
43,263
43,263 $992,000

Others Institutions Holding XNCR

# of Institutions
216
Shares Held
71.5M
Call Options Held
2.5K
Put Options Held
7.9K
View Full List

About Xencor Inc

XNCR Quotes by TradingView
  • Ticker XNCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,698,100
  • Market Cap $1.17B
  • Description
  • Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...
More about XNCR
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email